OPRX vs. ZFOX, DHX, RMNI, EGIO, RGP, ZH, EEX, GRVY, LQDT, and CASS
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include ZeroFox (ZFOX), DHI Group (DHX), Rimini Street (RMNI), Edgio (EGIO), Resources Connection (RGP), Zhihu (ZH), Emerald (EEX), Gravity (GRVY), Liquidity Services (LQDT), and Cass Information Systems (CASS). These companies are all part of the "business services, not elsewhere classified" industry.
ZeroFox (NASDAQ:ZFOX) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking.
ZeroFox presently has a consensus price target of $3.50, indicating a potential upside of 208.37%. OptimizeRx has a consensus price target of $15.86, indicating a potential upside of 70.14%. Given OptimizeRx's higher possible upside, analysts plainly believe ZeroFox is more favorable than OptimizeRx.
OptimizeRx received 138 more outperform votes than ZeroFox when rated by MarketBeat users. Likewise, 62.83% of users gave OptimizeRx an outperform vote while only 44.44% of users gave ZeroFox an outperform vote.
In the previous week, OptimizeRx had 7 more articles in the media than ZeroFox. MarketBeat recorded 7 mentions for OptimizeRx and 0 mentions for ZeroFox. ZeroFox's average media sentiment score of 0.00 beat OptimizeRx's score of 0.00 indicating that OptimizeRx is being referred to more favorably in the news media.
37.3% of ZeroFox shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 12.8% of ZeroFox shares are owned by company insiders. Comparatively, 4.4% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
ZeroFox has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
OptimizeRx has a net margin of -24.56% compared to OptimizeRx's net margin of -152.73%. ZeroFox's return on equity of -7.72% beat OptimizeRx's return on equity.
OptimizeRx has lower revenue, but higher earnings than ZeroFox. OptimizeRx is trading at a lower price-to-earnings ratio than ZeroFox, indicating that it is currently the more affordable of the two stocks.
Summary
OptimizeRx beats ZeroFox on 14 of the 18 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
